Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Fig. 3

Kaplan-Meier analyses of survival in the initial and maintenance therapy. A Progression-free survival of initial therapy (full analysis set, n = 46). B Progression-free survival of maintenance therapy (n = 27). C Overall survival of initial therapy (full analysis set, n = 46). CI, confidence interval

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us